Voloridge Investment Management’s Cymabay Therapeutics CBAY Stock Holding History

Voloridge Investment Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-382,472	Closed	-$4.19M	–	1654
2023 Q2	$4.19M	Sell	382,472 -261,340	-41%	-$2.43M	0.02%	737
2023 Q1	$5.61M	Buy	+643,812	New	+$5.15M	0.03%	640
2021 Q1	–	Sell	-195,637	Closed	-$1.12M	–	1717
2020 Q4	$1.12M	Sell	195,637 -197,275	-50%	-$1.49M	0.01%	929
2020 Q3	$2.85M	Buy	+392,912	New	+$2.1M	0.02%	603
2020 Q2	–	Sell	-34,525	Closed	-$51K	–	1569
2020 Q1	$51K	Sell	34,525 -57,334	-62%	-$96.3K	﹤0.01%	1042
2019 Q4	$180K	Buy	91,859 +27,468	+43%	+$103K	﹤0.01%	1009
2019 Q3	$330K	Buy	+64,391	New	+$390K	0.01%	902

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Voloridge Investment Management's CBAY Position: Q3 2023 in Review

Voloridge Investment Management sold out of Cymabay Therapeutics (CBAY) in Q3 2023, closing a stake of 382,472 shares — an estimated $4.19M sold.

Voloridge Investment Management first reported a position in CBAY in Q3 2019 and held it in 7 quarters. The position peaked at $5.61M in Q1 2023. 189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

Voloridge Investment Management reported no remaining Cymabay Therapeutics position as of Q3 2023 after selling out during the quarter.
Voloridge Investment Management sold 382,472 Cymabay Therapeutics shares in Q3 2023, an estimated $4.19M.
Voloridge Investment Management first reported a position in Cymabay Therapeutics in Q3 2019 and held it in 7 quarters.
Voloridge Investment Management's Cymabay Therapeutics position peaked at $5.61M in Q1 2023.
189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on Voloridge Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.